A5101567456- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Atherosclerosis and Cardiovascular Diseases
- Cardiovascular Disease and Adiposity
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Lipoproteins and Cardiovascular Health
- Monoclonal and Polyclonal Antibodies Research
- Apelin-related biomedical research
- Cytokine Signaling Pathways and Interactions
- Cell Adhesion Molecules Research
- Vascular Procedures and Complications
- Glycosylation and Glycoproteins Research
- Thyroid Cancer Diagnosis and Treatment
- Protease and Inhibitor Mechanisms
- Cardiac Health and Mental Health
- Cerebrovascular and Carotid Artery Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Chronic Kidney Disease and Diabetes
- Thyroid Disorders and Treatments
- Health Promotion and Cardiovascular Prevention
- Renal and Vascular Pathologies
- Healthcare Systems and Public Health
- Angiogenesis and VEGF in Cancer
Capital Medical University
2009-2025
Capital University
2025
Beijing Anzhen Hospital
2009-2023
Peking University First Hospital
2005
Peking University
2005
Background Individuals who present with acute myocardial infarction in the absence of standard modifiable cardiovascular risk factors (ie, SMuRF‐less) seem to have a significantly increased mortality; however, it remains unclear whether “SMuRF paradox” would be influenced by patients' baseline body mass index (BMI) status. Methods Using data from CCC‐ACS (Improving Care for Cardiovascular Disease China–Acute Coronary Syndrome) project November 2014 July 2019, we analyzed patients and without...
Abstract Background Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy. However, evidence on the impact of PCSK9 coronary plaque composition morphology is limited. Methods In this open-label randomized study, eligible patients with intermediate lesions elevated values were either alirocumab 75 mg Q2W plus (atorvastatin 20 mg/day or...
Background: Chronic kidney disease (CKD) is a strong predictor of mortality after percutaneous coronary intervention (PCI) or artery bypass grafting (CABG), but the relative efficacy 2 revascularization strategies in this context remains unknown. Methods and Results: The 1,069 patients with CKD undergoing for multivessel were evaluated. Of them, 532 treated 2-vessel (97 CABG, 435 PCI) 537 3-vessel (248 289 PCI). was defined as estimated glomerular filtration rate <60 ml/min. No differences...
The overall safety and efficacy of transradial coronary intervention (TRI) versus artery bypass grafting (CABG) for patients with unprotected left main (UPLM) disease and/or multivessel (MVD) presenting acute syndrome (ACS) have not been established. Consecutive ACS undergoing TRI drug-eluting stent (n = 1431) or CABG 651) UPLM MVD were included. A propensity-score matching was performed to adjust differences in baseline characteristics between the 2 cohorts, yielding 524 pairs matched...
We sought to compare the effects of smoking on clinical outcomes in women and men with coronary artery disease undergoing percutaneous intervention (PCI). prospectively followed up 10 369 patients elective PCI. All were stratified according status sex. The impacts long-term major adverse cardiovascular events (MACEs, composite all-cause death, myocardial infarction, or target vessel revascularization) assessed. Among 7773 2596 PCI, prevalence cigarette was 66.7% (n = 5185) 11.0% 286; P <...
To examine whether obesity has a similar effect on long-term prognosis between men and women undergoing percutaneous coronary intervention (PCI).We separately examined 3926 2157 PCI with drug-eluting stents January 2004 December 2006. All the patients were categorized according to BMI: normal weight (<25 kg/m(2)), overweight (25-29.9 obese (≥30 kg/m(2)). The primary endpoint was major adverse cardiovascular events (MACE), defined as composite of cardiac death nonfatal myocardial infarction....
Previous studies reported regional variations in in-hospital acute coronary syndrome (ACS) mortality, but the reasons for that were not clearly defined. We explored whether differences patient characteristics could explain variation. The Improving Care Cardiovascular Disease China (CCC)-ACS project is an ongoing national registry and quality improvement project, involving 150 tertiary hospitals from 30 provinces across China. applied a prediction model included patient-specific variables to...
Abstract Background Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated with significant greater reduction of LDL cholesterol levels and cardiovascular events, compared standard statin therapy. However, the evidence on impact PCSK9 coronary plaque composition morphology are limited. Methods In this prospective, open-label, randomized study, eligible patients intermediate lesions elevated values were to either alirocumab 75 mg Q2W plus therapy (alirocumab...
Objective: To compare the efficacy and safety of active transfer plaque (ATP) versus provisional stenting (PS) with drug-eluting stents (DES) for treatment coronary bifurcation lesions. Methods: A total 1 136 patients lesions hospitalized in 6 selected hospitals between January 2010 2014 were included this prospective observational trial, divided into either ATP (n=560) or PS group (n=576) accordingly. The primary endpoint was target lesion revascularization within year, second endpoints...
Background: Homeostasis of thyroid hormones has significant effects on the cardiovascular system. The aim this study was to investigate association between free triiodothyronine (FT3) and adverse events in patients with acute coronary syndrome (ACS) who were undergoing percutaneous intervention (PCI). Methods: A total 1701 ACS PCI included study. All divided into three groups according tertiles FT3 level: lowest tertile (FT3 <4.51 pmol/L), middle (4.51 pmol/L ≤ < 4.89 pmol/L) highest group...
Abstract Background Atherosclerosis (AS) is a systemic disease and the common cause of heart attacks, strokes peripheral vascular collectively referred to as cardiovascular diseases (CVD). In AS plaques, CD44 upregulated functionally activated on endothelial cells, smooth muscle macrophages. YN001 liposome encapsulated Rosuvastatin calcium which was initially approved for reduction cholesterol levels slowing progression atherosclerosis. being developed treatment by targeted enrichment in...